Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 20818913.
- Also identified by DOI 10.3109/14653249.2010.517518 and PMC identifier 3178185.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Because of the necessary immunodepletion prior to cord blood transplantation as well as the immaturity of cord blood immune cells, recipients experience a high incidence of viral infection in addition to complications observed after hematopoietic stem cell transplantation, such as relapse and graft-versus-host disease. We describe current immunotherapeutic approaches to treating these complications, including the generation of antigen-specific T cells from cord blood, redirecting cord blood T cells using chimeric antigen receptors, and generating cord blood-derived natural killer cells and regulatory T cells.
Medical subject headings
- Cord Blood Stem Cell Transplantation
- Graft vs Host Disease
- Immunotherapy, Adoptive
- Transplantation Conditioning
- Virus Diseases